GlassScriptPhysician profile
Debra S Brandt
NPI 1710918032
$14,925.08
in general payments reported to CMS, 2019-2025
30 companies · $1,875 in 2025
The $1,875 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.74 · 2020: $3,300 · 2021: $300 · 2022: $2,139 · 2023: $1,826 · 2024: $5,385 · 2025: $1,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,845 · Food and Beverage: $2,111 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,845.00 |
| Food and Beverage | $2,110.79 |
| Education | $130.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $9,140.24 | 2020-2025 | Enhertu, Tagrisso |
| Immunocore Limited | $2,023.16 | 2022-2024 | Kimmtrak |
| Daiichi Sankyo INC. | $1,066.65 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Athenex Pharmaceutical Division, LLC | $500.00 | 2020 | |
| Tempus Ai, INC | $305.70 | 2024 | Xt Cdx |
| Abbvie INC. | $249.75 | 2024-2025 | |
| Pfizer INC. | $179.24 | 2024-2025 | |
| Janssen Biotech, INC. | $146.16 | 2024-2025 | Tecvayli, Darzalex, Talvey |
| Lilly USA, LLC | $138.17 | 2019-2021 | |
| Glaxosmithkline, LLC. | $134.95 | 2022-2025 | Ojjaara |
| Celgene Corporation | $127.70 | 2024-2025 | Reblozyl, Pomalyst, Opdivo |
| Genzyme Corporation | $121.86 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $81.63 | 2021-2024 | Krazati, Augtyro, Opdualag |
| Amgen INC. | $80.64 | 2021-2023 | Kyprolis, Blincyto |
| Novartis Pharmaceuticals Corporation | $72.00 | 2023-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $71.93 | 2024-2025 | Ninlaro, Iclusig |
| Merck Sharp & Dohme LLC | $68.78 | 2021-2025 | Keytruda, Lynparza |
| Gilead Sciences, INC. | $59.38 | 2021 | |
| Genentech USA, INC. | $56.81 | 2025 | Columvi |
| Astellas Pharma US INC | $56.49 | 2023-2025 | Padcev, Xospata, Xtandi |
| Puma Biotechnology, INC. | $51.84 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $26.77 | 2024 | Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $25.68 | 2025 | |
| Immunogen, INC. | $25.00 | 2024 | Elahere |
| Tactile Systems Technology INC | $23.46 | 2025 | Nimbl, Flexitouch Plus |
| Mirati Therapeutics, INC. | $22.00 | 2023 | Krazati |
| Eisai INC. | $21.44 | 2022 | |
| Kyowa Kirin, INC. | $21.06 | 2024 | Poteligeo |
| Adaptive Biotechnologies Corporation | $14.30 | 2022 | |
| Seagen INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Brandt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.